Swiss National Bank’s Voyager Therapeutics VYGR Stock Holding History

Swiss National Bank’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-53,800	Closed	-$253K	–	2652
2021 Q1	$253K	Hold	53,800	–	–	﹤0.01%	2477
2020 Q4	$385K	Hold	53,800	–	–	﹤0.01%	2478
2020 Q3	$574K	Hold	53,800	–	–	﹤0.01%	2332
2020 Q2	$679K	Buy	53,800 +800	+2%	+$9.3K	﹤0.01%	2292
2020 Q1	$485K	Hold	53,000	–	–	﹤0.01%	2198
2019 Q4	$739K	Buy	53,000 +1,200	+2%	+$17.4K	﹤0.01%	2286
2019 Q3	$891K	Buy	51,800 +6,300	+14%	+$132K	﹤0.01%	2115
2019 Q2	$1.24M	Buy	45,500 +10,200	+29%	+$233K	﹤0.01%	1996
2019 Q1	$676K	Hold	35,300	–	–	﹤0.01%	2276
2018 Q4	$332K	Hold	35,300	–	–	﹤0.01%	2454
2018 Q3	$668K	Hold	35,300	–	–	﹤0.01%	2334
2018 Q2	$690K	Buy	35,300 +5,900	+20%	+$117K	﹤0.01%	2348
2018 Q1	$552K	Hold	29,400	–	–	﹤0.01%	2341
2017 Q4	$488K	Buy	+29,400	New	+$504K	﹤0.01%	2417

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Swiss National Bank's VYGR Position: Q2 2021 in Review

Swiss National Bank sold out of Voyager Therapeutics (VYGR) in Q2 2021, closing a stake of 53,800 shares — an estimated $253K sold.

Swiss National Bank first reported a position in VYGR in Q4 2017 and held it in 14 quarters. The position peaked at $1.24M in Q2 2019. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2021.

Swiss National Bank reported no remaining Voyager Therapeutics position as of Q2 2021 after selling out during the quarter.
Swiss National Bank sold 53,800 Voyager Therapeutics shares in Q2 2021, an estimated $253K.
Swiss National Bank first reported a position in Voyager Therapeutics in Q4 2017 and held it in 14 quarters.
Swiss National Bank's Voyager Therapeutics position peaked at $1.24M in Q2 2019.
78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2021.

Based on Swiss National Bank's 13F filing for Q2 2021, filed 6 Aug 2021.